 Dividend.com | Lilly Halts Drug Development After Failed Trial Inside INdiana Business (press release) The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy. There were no new safety findings, and the safety data were ... Lilly To Take $30M Charge After Relapse Cancer Drug Disappoints in Trial Enzastaurin, Eli Lilly's Lymphoma Drug Fails In Late-Stage Trial Lilly Halts Development of Lymphoma Drug After Phase III Failure |
